Takeda announces FDA approval of Gammagard Liquid ERC

Takeda (TAK) announced that the FDA has approved Gammagard Liquid ERC with less than or equal to two microgram/mL IgA in a 10% solution, the only ready-to-use liquid immunoglobulin therapy with low immunoglobulin A content, as replacement therapy for people two years of age and older with primary immunodeficiency.